Equity Components [Axis] Ordinary shares [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Range [Axis] Minimum [Member] Maximum [Member] Related Party [Axis] Controlling Shareholder [Member] Title of Individual [Axis] Board of Directors [Member] Plan Name [Axis] Employees [Member] Non Employees Member [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Property, Plant and Equipment, Type [Axis] Laboratory equipment [Member] Office equipment and furniture [Member] Computers and software [Member] Leasehold Improvements [Member] Executive Officer [Member] Non Employees Member [Member] Investment Type [Axis] U.S government and agency bonds [Member] Corporate bonds [Member] Subsidiary Sale Of Stock [Axis] IPO [Member] CEO [Member] Consultant Member [Member] Canada government bonds [Member] Other foreign government bonds [Member] Scenario [Axis] Mainly [Member] IIA [Member] Yissum [Member] Registration Payment Arrangement by Arrangement [Axis] Master Clinical Trial Services Agreement [Member] Clinical Development Master Services Agreement [Member] Agreement One [Member] Agreement Two [Member] Range [Axis] Subsequent Event [Member] FPO [Member] Private Placement [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Consolidated Entities [Axis] Subsidiaries [Member] Vehicles [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Shell Company Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Incorporation State Country Code Entity Interactive Data Current Document Annual Report Document Transition Report Document Shell Company Report Statement of Financial Position [Abstract] Assets CURRENT ASSETS: Cash and cash equivalents Bank deposits Marketable securities Receivables from collaborative arrangements Prepaid expenses and other current assets TOTAL CURRENT ASSETS NON-CURRENT ASSETS: Long term receivables Restricted long-term deposits Property and equipment, net Operating lease right-of-use assets Funds in respect of employee rights upon retirement TOTAL NON-CURRENT ASSETS TOTAL ASSETS Liabilities and shareholders' equity (capital deficiency) CURRENT LIABILITIES: Accounts payable Other accounts payable Current maturities of operating leases Loans from the controlling shareholder TOTAL CURRENT LIABILITIES LONG-TERM LIABILITIES: Operating leases liabilities Liability for employee rights upon retirement TOTAL LONG-TERM LIABILITIES COMMITMENTS TOTAL LIABILITIES SHAREHOLDERS' EQUITY: Ordinary shares, NIS 0.1 par value - authorized: 50,000,000 as of December 31, 2018 and 2019, respectively; issued and outstanding: 18,949,968 and 20,402,800 as of December 31, 2018 and December 31, 2019, respectively Additional paid-in capital Accumulated deficit TOTAL SHAREHOLDERS' EQUITY TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Ordinary shares, par value per share Ordinary shares, shares authorized Ordinary shares, shares issued Ordinary shares, shares outstanding Income Statement [Abstract] COLLABORATION REVENUES OPERATING EXPENSES Research and Development General and Administrative TOTAL OPERATING LOSS FINANCIAL INCOME, net LOSS BEFORE INCOME TAXES INCOME TAXES LOSS FOR THE YEAR BASIC AND DILUTED LOSS PER ORDINARY SHARE WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE Statement [Table] Statement [Line Items] Balance Balance, shares Loss for the year Stock split Stock split, shares Conversion of loans from the Controlling shareholder Conversion of loans from the Controlling shareholder, shares Issuance of shares due to in- process research and development acquired Issuance of shares due to in- process research and development acquired, shares Issuance of shares through an initial public offering, net of issuance costs Issuance of shares through an initial public offering, net of issuance costs, shares Exercise of options granted to employee Exercise of options granted to employee, shares Vesting of restricted shares Vesting of restricted shares, shares Issuance of shares through public offering, net of issuance costs Issuance of shares through public offering, net of issuance costs, shares Share-based compensation Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Loss Adjustments required to reconcile loss to net cash used in operating activities: Depreciation Changes in accrued liability for employee rights upon retirement Net changes in operating leases Changes in fair value of marketable securities In-process research and development acquired Finance expenses, net Changes in operating asset and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable, accrued expenses and other Advance payment Long term receivables Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Bank deposits Restricted long-term deposits Investments in marketable securities Proceeds from sales and maturity of marketable securities Amounts funded in respect of employee rights upon retirement Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of options granted to an employee Proceeds from issuance of shares through public offering, net of issuance costs Loans received from the controlling shareholder Net cash provided by financing activities EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AND RESRICTED CASH AT BEGINNING OF THE YEAR CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR Cash and Cash equivalents Restricted cash CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: Purchase of property and equipment Obtaining a right-of-use asset in exchange for a lease liability Conversion of loans from the controlling shareholder Acquisition of in-process research and development product candidate SUPPLEMENTARY INFORMATION: Interest received Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Investments, Debt and Equity Securities [Abstract] MARKETABLE SECURITIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Retirement Benefits [Abstract] EMPLOYEE SEVERANCE BENEFITS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS Revenue from Contract with Customer [Abstract] COLLABORATION AGREEMENTS Stockholders' Equity Note [Abstract] SHARE CAPITAL Income Tax Disclosure [Abstract] TAXES ON INCOME Payables and Accruals [Abstract] SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION Related Party Transactions [Abstract] RELATED PARTIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Use of estimates in the preparation of financial statements Functional and presentation currency Cash and cash equivalents Bank deposits Marketable securities Derivatives and hedging Property and equipment Impairment of long-lived assets Share-based compensation Research and development expenses Revenue recognition Income taxes Leases Loss per share Fair value measurement Concentration of credit risks Newly issued and recently adopted accounting pronouncements Schedule of Annual Depreciation Rates Schedule of Marketable Securities Summary of Changes in Fair Value of Marketable Securities Schedule of Debt Securities Schedule of Property and Equipment Schedule of Lease-related Assets And Liabilities Schedule of Lease Costs Schedule of Supplemental Cash Flow Information Related to Leases Schedule of Reconciles Undiscounted Cash Flows Schedule of Future Minimum Payments Under Operating Leases Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Assumptions Used to Estimate Fair Value Schedule of Stock Option Activity Schedule of Effect of Share-based Compensation Statements of Operations Schedule of Deferred Income Taxes Roll Forward of Valuation Allowance Schedule of Other Accounts Payables and Accruals Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Sale of Stock [Axis] Subsequent Event Type [Axis] Royalties Maturity Percentage of acquired shares Ordinary shares issued Per share price Additional ordinary shares purchased Procceds from Initial public offering, net of issuance costs Outstanding promissory note converted into ordinary shares Promissory note conversion price Net proceeds from issuance of ordinary shares and warrants Anti-dilutive shares Short-term deposits bear interest at an average annual rate Decrease in net cash used in investing activities Total hedged amount Restricted bank deposit Increase in Operating lease ROU assets and liabilities Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Statistical Measurement [Axis] Annual rate of depreciation Level 2 securities: Balance at beginning of the year Additions Sale or maturity Changes in fair value during the year Balance at end of the period Due within one year 1 to 2 years Total Depreciation and amortization expense Property and equipment, gross Accumulated depreciation and amortization Property and equipment, net Defined Contribution Plan [Table] Defined Contribution Plan Disclosure [Line Items] Amount of severance payment expenses Contribution Plan Loss Contingencies [Table] Loss Contingencies [Line Items] Royalties payable on the sale of products developed Percentage of royalties payments shall not exceed aggregate rant received Grant received Accumulated royalty expense Royalties pay for net sales related to patents Percentage of proceeds received for sub licence Lease expire Lease expense Operating lease agreements period Security deposit obligation under lease Bonus paid Consideration for services payment Expense recognized Percentage of gross profits related to sale of product Term of commercial sale of product Percentage of reimburse out-of-pocket expense Long term receivables Total consideration Percentage of expense recognized Amount pay to third party upon NDA submission of product Amount pay to approval of FDA on the first NDA product Percentage of future gross profit product sold Operating Leases Liabilities Current liabilities Long-term liabilities Non-current operating leases Weighted Average Remaining Lease Term Operating leases Weighted Average Discount Rate Operating leases Operating lease cost Cash paid for amounts included in the measurement of leases liabilities: Operating cash flows from operating leases For the year ended December 31, 2019 2020 2021 2022 2023 2024 Total minimum lease payments Less: amount of lease payments representing interest Present value of future minimum lease payments Less: Current leases obligations Long-term leases obligations Total 2019 2020 2021 Operating Lease Commitments Percentage of gross profits related to sale products Revenues recognized Share Split Bonus share issued for each outstanding share Odinary share issued under share incentive plan Maximum term of awards Shares available for future grant Option grants Option vested Exercise price Option vesting period Percentage of option vesting Percentage of unvested option granted Fair value of options granted Unrecognized compensation cost Compensation costs weighted average period to be recognized Intrinsic value outstanding option Intrinsic value exercisable option Amount of offering expense Net proceeds Value of one ordinary share Dividend yield Expected volatility Risk-free interest rate Expected term Number of options Options outstanding at beginning of year Granted Exercised Expired Forfeited Options outstanding at end of year Options exercisable at the end of the year Weighted-average exercise price Options outstanding at beginning of year Granted Exercised Expired Forfeited Options Outstanding at end of year Options exercisable at the end of the year Weighted-average remaining contractual term Options outstanding Granted Forfeited Options exercisable at the end of the year Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Income Tax Contingency [Table] Tax Credit Carryforward [Line Items] Corporate tax rates Tax benefit period Net carry forward tax losses In respect of: Net operating loss carry forward Research and development expenses Other Less - valuation allowance Net deferred tax assets Taxes On Income Roll Forward Of Valuation Allowance Balance Additions Accrued expenses Employees payables Other Other accounts payables and accruals Number of shares consideration in process research and development product Research and development Number of additional ordinary shares option Exercise price Additional ordinary shares purchased. Agreement One [Member] Agreement Two [Member] Amount pay to approval of FDA on the first NDA product. Amount pay to third party upon NDA submission of product. Amounts funded in respect of employee rights upon retirement, net. Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in two fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date. Cash inflow and outflow from bank deposits. Bank deposits [Policy Text Block] Bonus share issued for each outstanding share. Buildings And Land Member Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Changes in accrued liability for employee rights upon retirement. Cash inflow from changes in fair value of marketable securities. Clinical Development Master Services Agreement [Member] Consultant Member [Member] Decrease in net cash used in investing activities. Employee [Member] Employees Member [Member] Finance expenses, net. Financial expenses (income), net. IIA [Member] Issuance of shares due to in- process research and development acquired, shares. Issuance of shares through an initial public offering, net of issuance costs. Issuance of shares through an initial public offering, net of issuance costs, shares. Laboratory equipment [Member] Mainly [Member] Master Clinical Trial Services Agreement [Member] NATI [Member] Non Employees Member [Member] Non Employees Member [Member] Number of shares consideration in process research and development product. Office Furniture And Equipment Member Other foreign government bonds [Member] Percentage of expense recognized. Percentage of future gross profit product sold. Percentage of gross profits related to sale of product. Percentage of proceeds received for sub licence. Percentage of reimburse out-of-pocket expense. Percentage of royalties payments shall not exceed aggregate rant received. Percentage of unvested option granted. Preferred Enterprise [Member] The annual rate by which the asset depreciates. Restricted bank deposit. Royalties Maturity. Royalties pay for net sales related to patents. Royalties payable on the sale of products developed. Tabular disclosure of annual depreciation rates for property, plant and equipment. Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition Weighted average remaining contractual term for option Forfeited awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option grant awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Short-term deposits bear interest at an average annual rate. Tax benefit period. Term of commercial sale of product. Total consideration. Yissum [Member] Net changes in operating leases. Recognition of operating lease ROU and liabilities. Increase in Operating lease ROU assets and liabilities. Schedule of lease-related assets and liabilities [Table Text Block] Schedule of supplemental cash flow information related to leases [Table Text Block] Amount of lease payments representing interest. Present value of future minimum lease payments. Percentage of gross profits related to sale products. FPO [Member] Employee [Member] Assets, Current Assets, Noncurrent Assets [Default Label] Liabilities, Current Liabilities, Noncurrent Liabilities [Default Label] Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Financial Income Expenses Net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ChangesInAccruedLiabilityForEmployeeRightsUponRetirement NetChangesInOperatingLeases Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Finance Receivables Increase (Decrease) in Long-term Receivables, Current Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment BankDeposits Increase (Decrease) in Restricted Cash and Investments AmountsFundedInRespectOfEmployeeRightsUponRetirementNet Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Restricted Cash Employee [Member] [Default Label] Property, Plant and Equipment Disclosure [Text Block] Commitments Disclosure [Text Block] Income Tax Disclosure [Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Office Furniture And Equipment [Member] Marketable Securities, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Share-based Payment Arrangement, Director [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accounts Receivable, after Allowance for Credit Loss, Noncurrent Lessee, Operating Lease, Liability, Payments, Due AmountOfLeasePaymentsRepresentingInterest Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments Due Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2 Deferred Tax Assets, in Process Research and Development Deferred Tax Assets, Net Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Other Accrued Liabilities, Current Class of Warrant or Right, Exercise Price of Warrants or Rights